Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kyoto Trial of iPSC-derived dopaminergic progenitors with tacrolimus in Parkinson's disease
jRCT2091220385Completed
- Sponsor
- Kyoto University Hospital
- Start
- Sep 2018
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of tacrolimus in Parkinson's disease (PD), sponsored by Kyoto University Hospital. Primary endpoints: Cumulative rejection-free rate at 12 weeks and Cumulative rejection-free rate at 12 months. Started Sep 2018; status: completed.
02
Drugs
tacrolimus
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on jRCT2091220385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2091220385.